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OBJECTIVES Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in all-male study
cohorts, and thus the efficacy of I/H in women was unknown; 40% of the A-HeFT
(African-American Heart Failure Trial) cohort were women. We therefore compared
outcomes by gender and treatment.
BACKGROUND Fixed-dose combined I/H significantly reduced mortality and heart failure hospitalizations
and improved quality of life in 1,050 black patients with heart failure treated with background
neurohormonal blockade. Previous trials testing I/H were done in all-male study cohorts, and
thus the efficacy of I/H in women was unknown.
METHODS Baseline characteristics and medications were compared between men and women by I/H and
placebo treatment. Survival, time to first heart failure hospitalization, change in quality of life,
and event-free survival were compared by gender and treatment.
RESULTS At baseline, women had lower hemoglobin and creatinine levels; less renal insufficiency; and
higher body mass indexes, diabetes prevalence, and systolic blood pressures; but worse quality
of life scores. All-cause mortality was lower in women than in men treated with I/H but
without significant treatment interaction by gender. The primary composite score, which
weighted mortality, first heart failure hospitalization, and change in quality of life at
6 months, was similarly improved by I/H in men and women. First heart failure hospital-
ization and event-free survival (time to death or first heart failure hospitalization) were
similarly improved in both genders.
CONCLUSIONS Fixed-dose I/H improved heart failure outcomes in both men and women in A-HeFT. The
I/H significantly improved the primary composite score and event-free survival as well as
reduced the risk of first heart failure hospitalizations similarly in both genders. The I/H had
a slightly greater mortality benefit in women, but without a significant treatment interaction
by gender. (J Am Coll Cardiol 2006;48:2263–7) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.020Cardiology Foundation
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tomen make up 50% of the population of heart failure
atients; however, they are significantly under-represented
n heart failure clinical trials (1–3), with still greater under-
epresentation of ethnically diverse women. The hypothesis
hat isosorbide dinitrate/hydralazine (I/H) improved out-
omes in African American patients was generated by
eanalysis of the all-male V-HeFT (Vasodilator Heart
ailure Trial)-I and -II trials (4–6); thus, the effects of
ender on response to I/H was unknown. The A-HeFT
African-American Heart Failure Trial) (7) confirmed the
enefit of I/H in black heart failure patients. Importantly,
0% of the A-HeFT cohort (n  420) were women (1,2);
herefore, this analysis of outcomes by gender in A-HeFT
rovides unique insight into the effect of gender on response
o nitric oxide enhancing therapy for heart failure.
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tudy design. The A-HeFT study design, patient charac-
eristics, end point definitions, complete methodology, and
ain outcomes have been previously published (7). The
-HeFT was a randomized, placebo-controlled, double-
lind trial in self-identified African American patients with
lass III or IV heart failure receiving background neurohor-
onal inhibition.
After eligibility was confirmed, patients were random-
zed to receive either a fixed-dose combination of I/H
20 mg/37.5 mg, respectively) or a placebo, added to
ackground therapy, initiated at 1 tablet 3 times daily and
itrated up to 2 tablets 3 times daily over an 18-month
ollow-up.
The primary efficacy end point for the trial was a
omposite score weighting all-cause mortality, first hospi-
alization for heart failure, and change in quality of life at
months (7).
tatistical analysis. Analyses were based on the intention-
o-treat principle. Survival, time to either death or first
ospitalization for heart failure (event-free survival), and
ime to first hospitalization for heart failure were compared
y Kaplan-Meier survival analysis methods with the log-
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atient characteristics were displayed as counts (and per-
entages). Baseline characteristics and cause-specific mor-
ality were compared among groups within gender using
ither a 2-sample t test or Fisher exact test. Comparison
etween gender and treatment interaction by gender were
erformed using 2-way analysis of variance. Analysis of
omposite scores with categorical variables was performed
ith PROC LOGISTIC software (version 8.2, SAS Insti-
ute, Cary, North Carolina).
ESULTS
aseline characteristics are shown in Table 1. Differences by
ender but not treatment group assignment were observed
able 1. Baseline Characteristics of Male and Female Patients by
Characteristics
Ma
I/H
(n  290)
ge (yrs) 56.6  12.8
eight (kg)* 95.7  24.8
rimary cause of heart failure (% of patients)
schemic heart disease 28.3
ypertension 37.2
diopathic 23.8
alvular cause 2.8
ther 7.9
YHA functional class (% of patients)
II  III† 96.6
IV 3.4
iabetes mellitus (%)* 38.6
enal insufficiency (%)* 20.0
reatinine (mg/dl)* 1.4  0.57
trial fibrillation (%)‡ 17.9
jection fraction (%)* 23.2  7.1
VIDD/BSA (cm/m2) 3.16  0.54
MI* 30.7  7.8
emoglobin (g/dl)* 13.8  1.6
lood pressure (mm Hg)
Systolic‡ 125.8  17.4
Diastolic 77.2  10.7
LHF QoL score* 48.4  24.6
aseline medications (%)
Diuretic 92.8
ACE inhibitor or ARB 93.4
Beta-blockers 84.5
Digoxin 60.7
Spironolactone 38.6
lus-minus values represent mean  SD. Lower quality of life scores indicate bett
haracteristics. *p  0.01 comparing men with women. †New York Heart Associat
p  0.05 comparing men with women.
A-HeFT  African-American Heart Failure Trial; ARB  angiotensin receptor
Abbreviations and Acronyms
A-HeFT  African-American Heart Failure Trial
CI  confidence interval
HR  hazard ratio
I/H  isosorbide dinitrate/hydralazineurface area; I/H isosorbide dinitrate/hydralazine; LVIDD left ventricular internal diam
f Life score.n the following parameters: compared with men, women
ad slightly lower baseline hemoglobin and creatinine levels,
s well as a lower prevalence of renal insufficiency and atrial
brillation. Women had slightly higher body mass index,
iabetes prevalence, and systolic blood pressure. Screening
igure 1. Primary composite score by gender and treatment groups. The
ntire group (men plus women) treated with isosorbide dinitrate/
ydralazine (I/H) had a significantly improved the composite score (p 
.016) compared with the entire group (men plus women) in the placebo
rm. Women as a group had better composite scores than men (p 0.049);
owever, there was no gender-by-treatment interaction (p  0.806).
atment Groups (n  1,050)
 630) Female (n  420)
Placebo
(n  340)
I/H
(n  228)
Placebo
(n  192)
56.9  12.7 56.9  13.4 56.7  14.3
97.5  26.0 88.4  23.4 88.0  23.3
23.8 17.1 20.8
39.1 43.4 34.4
25.3 25.4 31.8
3.2 2.2 3.1
8.5 11.8 9.9
93.2 97.4 97.4
6.8 2.6 2.6
35.6 52.6 39.6
21.1 11.4 12.5
1.4  0.49 1.1  0.44 1.1  0.38
19.4 12.3 14.6
23.2  7.6 24.8  7.6 25.8  7.0
3.10  0.53 3.16  0.56 3.21  0.64
31.3  7.8 32.8  8.3 33.2  8.8
13.7  1.8 12.7  1.6 12.3  1.8
124.5  17.7 129.0  17.3 126.8  18.6
75.9  10.7 78.1  9.7 75.0  10.2
49.7  25.1 54.1  25.0 52.6  26.2
91.5 89.5 95.3
93.8 90.8 91.7
82.6 82.9 81.3
60.9 56.1 60.9
38.5 42.1 36.5
lity of life. There were no significant gender-by-treatment interactions in baseline
YHA) functional class II represented only 1% of the A-HeFT patient population.
r; ACE  angiotensin-converting enzyme; BMI  body mass index; BSA  bodyTre
le (n
er qua
ion (N
blocke
eter in diastole; MLHF QoL scoreMinnesota Living With Heart Failure Quality
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December 5, 2006:2263–7 African-American Heart Failure Trialjection fraction was slightly lower in men than women;
owever, left ventricular internal diameter in diastole nor-
alized to body surface area did not differ between the
enders. Baseline quality of life scores were slightly worse in
omen compared with men. Analysis of the interaction
etween gender and treatment group assignment showed no
ifferences in baseline characteristics.
The baseline primary composite score end point in the
otal group of women was significantly better than that in
he total group of men (p  0.049). Both genders had a
esponse to fixed-dose combined I/H with similar magni-
ude of improvement over placebo in the primary composite
core (Fig. 1). Components of the primary composite score
death, first heart failure hospitalization, and change in
uality of life at 6 months) are shown in Figure 2. Mortality
as reduced in both genders, but seemed to be reduced to
greater degree in women. First hospitalization for heart
ailure was significantly and similarly reduced in both
enders. Change in quality of life was improved by
reatment in both genders but did not reach the level of
igure 2. Components of the primary composite score by gender and treat
lacebo in each group. Mortality was reduced by I/H in both men and wo
as similarly reduced in both men and women, whereas change in quali
nteraction.Figure 3. Kaplan-Meier curves for survival by gender and treatment groignificance, likely because of the decrease in sample size
y subgroup analysis.
Survival by gender and treatment groups is shown in
igure 3. Survival was better in women in the I/H arm
ompared with women in the placebo arm (hazard ratio
HR] 0.33, 95% confidence interval [CI] 0.16 to 0.71, p 
.003), whereas for men the difference between treatment
nd placebo arms was directionally similar, but of lesser
agnitude (HR 0.79, 95% CI 0.46 to 1.35, p  0.385).
owever, there was no significant difference by gender (p
.303) or treatment interaction by gender (p  0.470).
igure 4 shows that the improvement in time to first heart
ailure hospitalization in the I/H arm was nearly identical
or both genders (HR men 0.60, 95% CI 0.42 to 0.89, p 
.005; HR women 0.62, 95% CI 0.41 to 0.96, p  0.03).
imilarly, event-free survival (time to death or first hospi-
alization for heart failure) (Figure 5) improved in both men
nd women in the I/H group (HR men 0.67, 95% CI 0.49
o 0.92, p  0.013; HR women 0.58, 95% CI 0.39 to 0.86,
 0.007).
groups. The p values compare isosorbide dinitrate/hydralazine (I/H) with
with a slightly greater effect in women. First heart failure hospitalization
life (QoL) was improved in both genders without gender-by-treatmentment
men,
ty ofups. HR  hazard ratio; I/H  isosorbide dinitrate/hydralazine.
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African-American Heart Failure Trial December 5, 2006:2263–7Mortality from any cause was low and without gender-
y-treatment interaction (Table 2). Women had signifi-
antly lower total mortality in the I/H arm, whereas men
ad a directionally similar trend.
The most common I/H associated adverse events (head-
che, dizziness) as well as placebo-associated headaches
ere more common in women than men, whereas hypoten-
ion frequency was similar in men and women.
ISCUSSION
he unique features of the A-HeFT study (7) included the
ocus on a single ethnic group for whom retrospective data
uggested an increased responsiveness to fixed dose I/H, an
xploration of the novel mechanistic approach of nitric
xide enhancement for heart failure therapy, and the inclu-
ion of the largest percentage of women (40%), as well as the
argest absolute number of African American women (n 
20), in a heart failure trial. Importantly, the V-HeFT I and
I trials, which provided the hypothesis-generating data for
he A-HeFT study, included only men (4–6). Thus, there
ere no clinical trial data examining the effect of I/H on
eart failure outcomes in women.
Figure 4. Kaplan-Meier curves for first hospitalization for heartigure 5. Kaplan-Meier curves for event-free survival (time to either death or he
s in Figure 3.The results of these analyses comparing heart failure
utcomes in men and women in the A-HeFT cohort show
hat fixed-dose combined I/H improved heart failure out-
omes in both men and women. There were no gender
ifferences between men and women in the benefit of I/H
n the primary composite score, time to first heart failure
ospitalization, and event-free survival. The I/H seemed
o have a more pronounced mortality benefit in women,
ut there was no significant treatment interaction by
ender; thus it is possible that this finding might be
ttributable to chance because of the low number of
eaths in the study.
Assessment of the impact of gender and/or race on
esponse to heart failure treatment has been hampered by
he low numbers of women and ethnic minorities in
andomized clinical trials (1–3,8). Post-hoc and meta-
nalyses have therefore been performed to provide insights
nto the impact of these 2 variables, with the recognition
hat small sample size and different study designs impose
imitations to interpretation (9).
Differences by gender and race in the impact of risk
actors, clinical features, outcomes, and response to treat-
by gender and treatment groups. Abbreviations as in Figure 3.art failure hospitalization) by gender and treatment groups. Abbreviations
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December 5, 2006:2263–7 African-American Heart Failure Trialent (1,3,6,8–11) have been documented in patients with
eart failure. Thus, diabetes increases the risk of heart
ailure to a much greater extent in women than men (3), and
omen with heart failure experience greater functional
mpairment as well as poorer quality of life than men (3).
omparisons of men and women with nonischemic
ardiomyopathies show significantly better survival in
omen; however, both genders with ischemic cardiomy-
pathies have equally poor outcomes. Comorbidities such
s renal insufficiency, anemia, and diabetes have all been
hown to adversely impact heart failure outcomes (3). In
he A-HeFT cohort, there were differences between men
nd women in baseline clinical characteristics, but no
onsistent pattern that would predict a differential re-
ponse to I/H by gender.
Importantly, in contrast with what has been reported in
he literature (3), there were no gender differences in
aseline medications and there were no gender-by-
reatment assignment group interactions. Patients in both
rms of the trial were equally well treated with background
eurohormonal blockade. Thus, the very significant im-
rovement in survival in this cohort strongly suggests
lternative or additional mechanisms of progression of heart
ailure that are responsive to fixed-dose combined I/H.
These studies emphasize the importance of inclusion of
dequate numbers of subpopulations (whether defined by
ender or ethnicity) to probe for differences in drug respon-
iveness (12). It was especially important to include an
dequate sample of women in the A-HeFT trial because the
riginal observation of enhanced efficacy of I/H in African
mericans was made in all-male cohorts (4–6). This
nalysis of outcomes in 420 African American women with
ow ejection fractions and dilated left ventricles shows
mproved morbidity and mortality in both genders and
rovides strong evidence for the use of fixed-dose I/H in
able 2. Cause-Specific Mortality by Gender and Treatment Gro
Male
I/H
(n  290)
Placebo
(n  340)
otal deaths 22 32
V deaths 18 28
SCD 14 17
Pump failure 3 8
MI 0 1
CVA 1 2
on-CV deaths 4 4
umbers indicate events. Men versus women, p  0.049. Gender-by-treatment inte
ith I/H to placebo.
CV  cardiovascular; CVA  cerebrovascular accident; I/H  isosorbide dinitrafrican American men and women.eprint requests and correspondence: Dr. Anne L. Taylor,
niversity of Minnesota Medical School, C694 Mayo Memorial
uilding, Mayo Mail Code 293, 420 Delaware Street, SE, Min-
eapolis, Minnesota 55455. E-mail: taylo135@umn.edu.
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